E Fund Management Co. Ltd. Acquires 646 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

E Fund Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 38.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,339 shares of the biopharmaceutical company’s stock after buying an additional 646 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $2,458,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in REGN. West Paces Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. Sachetta LLC raised its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Finally, Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on REGN shares. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and set a $1,282.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,111.30.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,026 shares of company stock worth $11,498,705. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $1,146.75 on Wednesday. The company has a fifty day simple moving average of $1,128.09 and a 200 day simple moving average of $1,028.93. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company has a market cap of $126.36 billion, a P/E ratio of 33.88, a PEG ratio of 3.97 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same period last year, the business earned $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.